Stock listing
ZBIO Stock Price, News, Filings & Events — Zenas Biopharma, Inc.
Selected listing: ZBIO · BOATS · USD · US
This page tracks Zenas Biopharma, Inc.'s ZBIO:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ZBIO:BOATS. ZBIO:BOATS is the stock-level entry point for investors researching Zenas Biopharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Zenas Biopharma, Inc. is a public company traded under the ticker ZBIO in the American market. The company has a market capitalization of approximately $1.81 billion. Zenas Biopharma focuses on developing innovative biopharmaceuticals to address unmet medical needs.
- Ticker
- ZBIO:BOATS
- Asset type
- Stock
- Market cap
- $2.03B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Zenas Biopharma, Inc. ZBIO:BOATS stock context
This page tracks Zenas Biopharma, Inc.'s ZBIO:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ZBIO:BOATS. ZBIO:BOATS is the stock-level entry point for investors researching Zenas Biopharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Zenas Biopharma, Inc. is a public company traded under the ticker ZBIO in the American market. The company has a market capitalization of approximately $1.81 billion. Zenas Biopharma focuses on developing innovative biopharmaceuticals to address unmet medical needs.
Latest news from Zenas Biopharma, Inc.
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
September 8, 2026
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD),...
June 2, 2026
Zenas BioPharma Announces Submission of Biologics License Application to U.S. FDA for Obexelimab in IgG4-RD
May 29, 2026
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
May 28, 2026
Research Zenas Biopharma, Inc.
Zenas Biopharma, Inc. investor report
Review AI stock analysis and investor report context for ZBIO:BOATS.
Zenas Biopharma, Inc. company profile
View the public company page for Zenas Biopharma, Inc. on 6ix.
Zenas Biopharma, Inc. news
Read company news and market updates connected to Zenas Biopharma, Inc..
Zenas Biopharma, Inc. investor events
Find investor webinars, events, and replay context for Zenas Biopharma, Inc..